Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis.

Gutman J, Kovacs S, Dorsey G, Stergachis A, Ter Kuile FO.

Lancet Infect Dis. 2017 Feb;17(2):184-193. doi: 10.1016/S1473-3099(16)30378-4. Epub 2016 Nov 17.

2.

Malaria-Infected Mice Are Cured by a Single Low Dose of a New Silylamide Trioxane Plus Mefloquine.

Woodard LE, Mott BT, Singhal V, Kumar N, Shapiro TA, Posner GH.

Pharmaceuticals (Basel). 2009 Dec 21;2(3):228-235.

3.

User and Provider Acceptability of Intermittent Screening and Treatment and Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine to Prevent Malaria in Pregnancy in Western Kenya.

Hill J, Hoyt J, Achieng F, Ouma P, L'lanziva A, Kariuki S, Desai M, Webster J.

PLoS One. 2016 Mar 17;11(3):e0150259. doi: 10.1371/journal.pone.0150259. eCollection 2016.

4.

Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim(®)) in the treatment of uncomplicated malaria at public health facilities in four African countries.

Adjei A, Narh-Bana S, Amu A, Kukula V, Nagai RA, Owusu-Agyei S, Oduro A, Macete E, Abdulla S, Halidou T, Sie A, Osei I, Sevene E, Asante KP, Mulokozi A, Compaore G, Valea I, Adjuik M, Baiden R, Ogutu B, Binka F, Gyapong M.

Malar J. 2016 Jan 27;15:43. doi: 10.1186/s12936-016-1099-7.

5.

Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study.

Ogutu BR, Onyango KO, Koskei N, Omondi EK, Ongecha JM, Otieno GA, Obonyo C, Otieno L, Eyase F, Johnson JD, Omollo R, Perkins DJ, Akhwale W, Juma E.

Malar J. 2014 Jan 28;13:33. doi: 10.1186/1475-2875-13-33.

6.

Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria.

Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D.

Cochrane Database Syst Rev. 2014 Jan 20;(1):CD010927. doi: 10.1002/14651858.CD010927. Review.

7.

Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies.

Naing C, Racloz V, Whittaker MA, Aung K, Reid SA, Mak JW, Tanner M.

PLoS One. 2013 Dec 3;8(12):e78819. doi: 10.1371/journal.pone.0078819. eCollection 2013. Review.

8.

Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011-2012: association with molecular markers.

Lim P, Dek D, Try V, Eastman RT, Chy S, Sreng S, Suon S, Mao S, Sopha C, Sam B, Ashley EA, Miotto O, Dondorp AM, White NJ, Su XZ, Char MC, Anderson JM, Amaratunga C, Menard D, Fairhurst RM.

Antimicrob Agents Chemother. 2013 Nov;57(11):5277-83. doi: 10.1128/AAC.00687-13. Epub 2013 Aug 12.

9.

MMV in partnership: the Eurartesim® experience.

Ubben D, Poll EM.

Malar J. 2013 Jun 19;12:211. doi: 10.1186/1475-2875-12-211.

10.

Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.

Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, Tappero JW, Sandison TG, Lindegardh N, Nosten F, Aweeka FT, Parikh S.

J Infect Dis. 2013 Jun 1;207(11):1646-54. doi: 10.1093/infdis/jit078. Epub 2013 Feb 27.

11.

Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia.

Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, Setiabudy R, Nurleila S, Ekawati LL, Elyazar I, Farrar J, Sudoyo H, Baird JK.

Antimicrob Agents Chemother. 2013 Mar;57(3):1128-35. doi: 10.1128/AAC.01879-12. Epub 2012 Dec 17.

12.

Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010.

Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, Ringwald P.

Antimicrob Agents Chemother. 2013 Feb;57(2):818-26. doi: 10.1128/AAC.00686-12. Epub 2012 Dec 3.

13.
14.

The global pipeline of new medicines for the control and elimination of malaria.

Anthony MP, Burrows JN, Duparc S, Moehrle JJ, Wells TN.

Malar J. 2012 Sep 7;11:316. doi: 10.1186/1475-2875-11-316. Review.

15.
16.

In vitro metabolism of piperaquine is primarily mediated by CYP3A4.

Lee TM, Huang L, Johnson MK, Lizak P, Kroetz D, Aweeka F, Parikh S.

Xenobiotica. 2012 Nov;42(11):1088-95. doi: 10.3109/00498254.2012.693972. Epub 2012 Jun 6.

17.

Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.

Pascual A, Parola P, Benoit-Vical F, Simon F, Malvy D, Picot S, Delaunay P, Basset D, Maubon D, Faugère B, Ménard G, Bourgeois N, Oeuvray C, Didillon E, Rogier C, Pradines B.

Malar J. 2012 Feb 14;11:45. doi: 10.1186/1475-2875-11-45.

18.

Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria.

Tarning J, Zongo I, Somé FA, Rouamba N, Parikh S, Rosenthal PJ, Hanpithakpong W, Jongrak N, Day NP, White NJ, Nosten F, Ouedraogo JB, Lindegardh N.

Clin Pharmacol Ther. 2012 Mar;91(3):497-505. doi: 10.1038/clpt.2011.254. Epub 2012 Jan 18.

19.

Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.

Slack RD, Mott BT, Woodard LE, Tripathi A, Sullivan D, Nenortas E, Girdwood SC, Shapiro TA, Posner GH.

J Med Chem. 2012 Jan 12;55(1):291-6. doi: 10.1021/jm201214d. Epub 2011 Dec 15. Erratum in: J Med Chem. 2012 Feb 23;55(4):1788. Triphati, Abhai [corrected to Tripathi, Abhai].

20.

Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis.

Makanga M, Bassat Q, Falade CO, Premji ZG, Krudsood S, Hunt P, Walter V, Beck HP, Marrast AC, Cousin M, Rosenthal PJ.

Am J Trop Med Hyg. 2011 Nov;85(5):793-804. doi: 10.4269/ajtmh.2011.11-0069.

Supplemental Content

Support Center